I am a healthcare professional in the UK
I am a patient or member of the public
1 minute
The European Society for Clinical Virology (ESCV) 2025 Conference Highlights
Summary of highlights from the ESCV 2025 Conference; 17th-20th September; Thessaloniki, Greece, by Dr. Lucy Rivett and Kelly Bicknell.
Dr Lucy Rivett, Virology and Infectious Diseases Consultant at UKHSA and Cambridge University Hospitals NHS Trust and Kelly Bicknell, Consultant Clinical Scientist in Virology at Portsmouth Hospital University NHS Trust, discuss their selected topics from the ESCV 2025 Conference and how they may impact current practice in the UK.
Areas covered include CMV in transplantation, viral hepatitis and emerging infections.
Brightcove Video
References:
27th Annual ESCV (2025) Final Programme
27th Annual ESCV (2025) Abstract Book
The Fourth International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation (Kotton et al. 2025)
Jackson R, et al. J Clin Virol 2025:181:105876
Songtanin B, et al. J Viral Hepat 2025;32(8):e70051
EASL Congress 2025 Abstract Book Version_2_7_5
Sandmann L, et al. Hepatology 2025;81(2):E32-E33
Co ACG, et al. Lancet Infect Dis 2025;25:e381-e382
You might be interested in
1 minute
download
This concise guide to LIVTENCITY® (maribavir) is designed for clarity and ease of use. It summarises key insights from the Phase 3 SOLSTICE trial, including efficacy outcomes, safety data, and practical dosing guidance.
article
6 minutes
A summary of the safety profile of LIVTENCITY, including adverse event data and tolerability findings from clinical studies.
article
5 minutes
Key efficacy outcomes from clinical trials evaluating LIVTENCITY in patients with post-transplant CMV, including virologic response and treatment comparisons.
article
3 minutes
CMV is one of the most common infections experienced by transplant recipients
article
4 minutes
An overview of the pivotal Phase 3 SOLSTICE trial, outlining the study design, patient population, and methodology that underpin the clinical evidence for LIVTENCITY.
